Abstract
Since the 1980s there has been a drive toward personalized targeted therapy for cancer. “Targeted cancer therapy” originally focused on inhibiting essential tumor survival factors, primarily protein tyrosine kinases. The complexity and rapid mutability of tumors, however, enable them to develop resistance to tyrosine kinase inhibitors (TKIs), even when these are multitargeted or applied in combination. This has led to the development of targeted cancer immunotherapy, to enhance immune surveillance against the tumor. In this paper, we provide a personal view of the development of targeted therapy, from TKIs to targeted immunotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 11579-11586 |
| Number of pages | 8 |
| Journal | Proceedings of the National Academy of Sciences of the United States of America |
| Volume | 116 |
| Issue number | 24 |
| DOIs | |
| State | Published - 11 Jun 2019 |
Bibliographical note
Publisher Copyright:© 2019 National Academy of Sciences. All rights reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cancer
- Immunotherapy
- Targeted therapy
- Tyrosine kinase
- Tyrphostin
Fingerprint
Dive into the research topics of 'My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver